A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-09-22) →
What happened
NGeneBio updated the terms of a new share issuance to raise US$5.95M, about 28.3% of its market value.
For context, this raise equals about 28.3% of the company's market value, which is the rough scale of potential new-share dilution.
| Instrument | Share issuance |
|---|---|
| Raise amount | US$5.95M (≈$6M) |
| vs. market value | 28.3% |
| Filed | 2026-09-07, [Amended] Material event report (rights offering) |
| Source | DART rcept 20260907000199 → open original filing |
Versions of this filing
- 2026-04-27Original
- 2026-07-02Amendment 1
- 2026-07-16Amendment 2
- 2026-07-20Amendment 3
- 2026-09-07Amendment 4 (this page)
- 2026-09-22Amendment 5
Source: DART. Information only, not investment advice.